Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCR5 | P51681 | 3/20 | 0.38 |
| ▸ | NR1I2 | O75469 | 5/20 | 0.38 |
| ▸ | GPR119 | Q8TDV5 | 4/20 | 0.38 |
| ▸ | JAK2 | O60674 | 1/20 | 0.36 |
| ▸ | JAK1 | P23458 | 1/20 | 0.36 |
| ▸ | SPR | P35270 | 1/20 | 0.35 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.35 |
| ▸ | TERT | O14746 | 1/20 | 0.35 |
| ▸ | PRMT5 | O14744 | 1/20 | 0.35 |
| ▸ | WDR77 | Q9BQA1 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13196711 | 1.00 | CCR5 (0.38) | CCR5NR1I2GPR119JAK2JAK1 | |
| SCHEMBL2799706 | 0.89 | HTR4 (0.35) | CCR5GPR119 | |
| SCHEMBL2798097 | 0.89 | HTR4 (0.35) | CCR5GPR119 | |
| SCHEMBL13196707 | 0.89 | CCR5 (0.36) | CCR5NR1I2GPR119JAK2JAK1 | |
| SCHEMBL13200887 | 0.89 | CCR5 (0.36) | CCR5NR1I2GPR119JAK2JAK1 | |
| SCHEMBL13196697 | 0.85 | JAK2 (0.42) | CCR5NR1I2GPR119JAK2JAK1 | |
| SCHEMBL2799651 | 0.79 | SLC18A3 (0.33) | CCR5 | |
| SCHEMBL13200533 | 0.77 | TACR1 (0.48) | — | |
| SCHEMBL13196692 | 0.73 | MEN1 (0.39) | NR1I2GPR119TERT | |
| SCHEMBL13200865 | 0.73 | MEN1 (0.39) | NR1I2GPR119TERT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100197724-A1 | 6.5 -PYRROLOPIPERIDINE TACHYKININ RECEPTOR ANTAGONISTS | BAO JIANMING | 2010-08-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100197724-A1 | 6.5 -PYRROLOPIPERIDINE TACHYKININ RECEPTOR ANTAGONISTS | TACR1, TACR2, HTR1D | CCR5 276/4885NR1I2 2053/4885GPR119 910/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.